One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%

Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients. The results could help boost sales of one of the company's top moneymakers. Repatha, which is approved to cut high LDL cholesterol, brought in $3.02 billion in sales last year. That represented more than 8% of…